|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
Mechanistically, DNMT3A-mediated promoter hypermethylation was responsible for the downregulation of PGLYRP2 in HCC.
|
31479523 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
miR-450 could inhibit proliferation, invasion, and migration via regulating DNMT3a in hepatocarcinoma cells, which provided a theoretical basis for the treatment of liver cancer.
|
31303764 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
MiR-876-5p acts as an inhibitor in hepatocellular carcinoma progression by targeting DNMT3A.
|
29724530 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated that the expression levels of DNA methyltransferase 3a (DNMT3a), a possible target gene for miR‑200b, were significantly higher in HCC tissue samples, as compared with those in NL and PT tissue samples.
|
26986232 |
2016 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
HBx expression was found to have a significant inverse correlation with miR-101 expression in HBx-expressing HepG2 compared to control HepG2 cells. miR-101 expression was frequently down-regulated in HBV-related HCC tissues compared to adjacent noncancerous hepatic tissues and had a significant inverse correlation with DNMT3A expression in HBV-related HCCs.
|
23124077 |
2013 |
|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
DNMT1 and DNMT3A may play important roles in the process of HBx inducing hypermethylation of the p16(INK4A) promoter in the early stages of HBV-associated HCC.
|
19732323 |
2010 |
|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma.
|
19139273 |
2009 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results first suggest that hepatocarcinogenesis involves an increased expression of DNMT1, DNMT3a and DNMT3b mRNA and a progressive increase in the number of methylated genes from normal liver, chronic hepatitis/cirrhosis to HCC and secondly that an increase in the DNMT3a and DNMT3b mRNA levels in HCCs relative to their non-cancerous tissues may be a predictor of poor survival.
|
17549390 |
2007 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
DNMT1 and DNMT3a were immunoreactive in 100 and 48% of HCCs and 52 and 0% of non-neoplastic liver tissues.
|
15885882 |
2006 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, the significantly decreased cytoplasmic immunoreactivity for Dnmt3a in high-grade DNs and HCCs can be used as a diagnostic adjunct.
|
12605361 |
2003 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
RGD |
Immunoblot assay showed that the levels of DNMT1, DNMT3a, and DNMT3b proteins in the hepatoma were 5-, 10-, and 4-fold higher, respectively, than in the liver.
|
11844796 |
2002 |
|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
These data suggest that overexpression of DNMT1 and DNMT3a, DNA hypermethylation on CpG islands, and DNA hypomethylation on pericentromeric satellite regions are early events during hepatocarcinogenesis, and that reduced expression of MBD4 may play a role in malignant progression of HCC.
|
11230735 |
2001 |